{"title":"Introductory Chapter: Updates and New Insights from WHO 2017 Peripheral T-Cell Lymphoma Classification","authors":"P. Piccaluga","doi":"10.5772/INTECHOPEN.86262","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.86262","url":null,"abstract":"Peripheral T-cell lymphomas (PTCLs) are relatively rare disorders, representing around 10% of all lymphomas worldwide; however, they are relatively common in specific geographic areas, including Asia, the Caribbean basin, and scattered areas in Europe where HTVL1 is endemic. In the latest edition of the World Health Organisation (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues, edited in 2017, nodal, extra nodal and leukaemia forms are listed. Specifically, as many as 31 entities are listed among PTCLs [1]. Compared with the previous edition, in the current classification, a few but quite relevant novelties have been introduced. Generally speaking, as already observed for B-cell derived malignancies, recent discoveries from molecular genetic studies led to a better definition of certain entities and clearly defined a pivotal role for cellular derivation in tumour classification. In the following, the main updates concerning non-cutaneous PTCLs will be briefly discussed.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125075601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Overview of T-cell Lymphomas","authors":"N. Somasundaram, S. Lim","doi":"10.5772/INTECHOPEN.85058","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.85058","url":null,"abstract":"T-cell lymphomas are a mixed bag of diseases with a similar origin but diverse in biology and behavior. This review aims to highlight the key changes to the WHO classification and summarize the therapeutic paradigm as of the time of writing in November 2018. subtypes. Two distinct molecular subgroups have been identified in PTCL NOS with differing clinical outcomes and prognosis. High expression of transcription factor GATA3 was associated with worse clinical outcomes, while TBX2 expression enriched by IFNgamma and NfKB pathways was associated with better survival. These findings provide insight into a disease which has been a diagnosis of exclusion, with poor clinical outcomes and minimal advances in treatment.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"131 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132284333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extranodal T/NK Lymphomas","authors":"S. Novelli","doi":"10.5772/INTECHOPEN.85541","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.85541","url":null,"abstract":"Extranodal T/NK lymphomas comprise infrequent and highly aggressive entities such as extranodal NK/T-cell lymphoma nasal type, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, intestinal T-cell lymphoma NOS, and hepatosplenic T-cell lymphoma. Except for NK/T lymphoma nasal type, there is scarce evidence to support a specific therapeutic regimen in first line and relapse. As the only potentially curative therapy is allogeneic hematopoietic stem cell transplantation, it should be assessed in relapsing/ refractory NK/T lymphoma nasal type and in the first line after remission in the other extranodal NK/T lymphomas.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122262316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Unique Therapeutic Approaches for Targeting Epigenetic Machinery in T-cell Lymphoma","authors":"Jacob C. Cogan, J. Amengual","doi":"10.5772/INTECHOPEN.85059","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.85059","url":null,"abstract":"Growing knowledge on T-cell lymphoma (TCL) biology has led to the understanding that TCLs harbor derangements in proteins modulating epigenetic control. Some such derangements include mutations in TET2, IDH2, DNMT3A, EP300, and CBP. In addition, overexpression of epigenetic modifiers such as EZH2 also exists in the absence of mutations. HDAC inhibitors are approved for use in relapsed T-cell lymphoma. There may be unique methods to targeting epigenetic derangements using new agents such as DNMT, EZH2, IDH, and BET inhibitors to name a few. In this chapter, we will review and explore unique methods for therapeutic targeting of epigenetic machinery for TCL.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132930315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Precision Medicine Concepts in T-Cell Lymphoma","authors":"P. Staber","doi":"10.5772/INTECHOPEN.85543","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.85543","url":null,"abstract":"Modern oncology witnesses an increasing number of new effective anticancer drugs targeting specific oncogenic pathways. Despite these advances, real-world experience with targeted single agents is disappointing since drug resistance usually occurs after a short time. This is particularly true for patients with refractory or relapsed T-cell lymphoma (TCL) who so far could not benefit from novel agents and demonstrate a short survival time of only 3 months. The novel genetic information gained from genome-wide high-throughput techniques has greatly improved our understanding of TCL. However, if precision medicine strategies are based solely on genetics, it runs into two major challenges: (1) the heterogeneity within the cancer of an individual patient and (2) the incomplete understanding of the degree of con-tribution of a specific mutation to a tumor phenotype. Next-generation functional drug screening (ngFDS) aims to address these problems. Studies that proof the clinical utility of ngFDS are currently limited. The following chapter aims to discuss recent advances of ngFDS and to line out its potential for TCL patients. non-randomized and therapies. of","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130149907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gamma-Delta T-cell Lymphoma: An Overview","authors":"P. Ramachandran, Alok Aggarwal, Jen-Chin Wang","doi":"10.5772/INTECHOPEN.85542","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.85542","url":null,"abstract":"Gamma-delta T-cell lymphomas are very rare and aggressive T-cell neoplasms with complex heterogenicity and diagnostic complexity. Gamma-delta T lymphocytes originate from CD4 − CD8 − (double negative) thymocytes in the bone marrow and are distinct from alpha beta subtype. Four entities of gamma-delta lymphomas recognized by 2016 WHO classification of lymphoid neoplasms include: hepatosplenic T γδ lymphoma (HS γδ TL), primary cutaneous gamma-delta TCL (PCTCL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) and large granular lymphocytic leukemias (T-LGL). Extensive literature search based on small case series and case reports identifies few more subtypes of gamma-delta T-lymphomas which were not previously classified by World Health Organization. There remains a critical gap in our understanding of the subtypes of gamma-delta T-cell lymphomas and a lack of updated summarization. In this review, we summarize in detail on the classification, biology, heterogenicity, diagnosis, clinical behavior and treatment options of these rare but clinically important entities.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131229128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel Aurora Kinase Inhibitor-Based Combination Therapies for PTCL","authors":"D. Mahadevan, Pavan Tenneti, L. Davis","doi":"10.5772/INTECHOPEN.81805","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.81805","url":null,"abstract":"Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell non-Hodgkin’s lymphomas (T-NHL) that display distinct clinical and biological features. Despite a detailed understanding of PTCL transformation, there is no current accepted standard of care for newly diagnosed or relapsed/refractory (r/r) patients. PTCL are highly proliferative neoplasms with an immunosuppressive microenvironment that elaborates drug resistance to current therapies with poor outcomes. Aurora kinases (AKs) are a family of mitotic oncogenic serine/threonine kinases (A, B/C) that are aberrantly expressed in PTCL, providing a growth advan-tage. Alisertib, an AK-A inhibitor, blocks the mitotic phase of the cell cycle resulting in apoptosis. Preclinical and clinical trials in PTCL demonstrated an ~30% response rate in r/r PTCL similar to other investigational agents. In order to improve response rates, alisertib-based combination therapies were tested with HDAC inhibitors, romidepsin and vorinostat, in phase Ib trials. To improve response rates to alisertib, we evaluated alisertib-induced polyploidy as a drug resistance mechanism by targeting microtubules with vincristine. In addition, we also targeted immunosup-pression-induced proliferation with an anti-PD-L1 antibody and PI3K inhibition in PTCL. Targeting aberrant proliferation and immunosuppression is a novel strategy that warrants evaluation in clinical trials for PTCL, an unmet clinical need.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124244884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anaplastic Large Cell Lymphoma","authors":"S. Turner","doi":"10.5772/INTECHOPEN.81382","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.81382","url":null,"abstract":"Anaplastic large cell lymphoma (ALCL) describes a distinct group of T cell lymphomas characterised by cell surface expression of CD30. At least three entities of ALCL exist, with similar cellular morphology but varying clinical courses and pathology: systemic ALCL, anaplastic lymphoma kinase (ALK)-positive, systemic ALCL ALK− and primary cutaneous ALCL. A fourth provisional entity associated with breast implants has been proposed, named breast implant-associated (BIA)ALCL. ALCL have varying clinical outcomes, affect both children and adults, and range from being well-characterised at the genetic level to relatively unknown, predominantly due to the relative rarity of this group of malignancies. Current therapeutic approaches include standard chemotherapeutic agents as well as novel drugs including monoclonal antibodies and kinase inhibitors.","PeriodicalId":315536,"journal":{"name":"Peripheral T-cell Lymphomas","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134467389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}